MANNKIND CORP

This Delaware-incorporated biopharmaceutical company develops and commercializes treatments for chronic diseases with significant unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload associated with heart failure and chronic kidney disease. The company operates a portfolio spanning both marketed products and pipeline candidates, with a particular focus on inhaled and injectable delivery mechanisms for serious conditions.

The company's marketed products include Afrezza, an inhaled insulin powder for glycemic control in adults with diabetes; the V-Go wearable insulin infusion device; Tyvaso DPI, a dry-powder formulation for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and FUROSCIX, a furosemide injection for fluid management in heart failure and chronic kidney disease patients. The pipeline includes MNKD-201, a dry-powder formulation of nintedanib for idiopathic pulmonary fibrosis, and MNKD-701. The company maintains collaboration agreements with United Therapeutics Corporation for Tyvaso DPI development and commercialization, and with Thirona for pulmonary fibrosis therapeutic evaluation.

Headquartered in Danbury, Connecticut, the company operates with approximately 403 full-time employees and is listed on the Nasdaq. The organization structures its activities around chronic disease management across multiple therapeutic areas, with revenue generation primarily from marketed pharmaceutical products and device sales.